prostate cancer) (C60-63), 10.7% had malignant neoplasms of digestive organs (C15-26) and 8,4% showed malignant neoplasms of ill-defined, secondary and unspecified sites (C76-80). The outpatient diagnosis rate for CLL was 94.9%, inpatient rate 0.6% and in-and outpatient rate 4.6%. Overall, 266 of 1,405 pts (18.9%) (175 men [65.8%], 91 women [34.2%]) received chemotherapy in 2012 (ATC Code L01* 74.1%, PZN 9999092 23.0%, OPS 854* 2.9%). Most patients received outpatient treatment (94.0%), with 5.3%of patients received both out-and inpatient treatment and 0.7% inpatient treatment. The most commonly used treatments were rituximab (26.7%), bendamustine (20.2%), chlorambucil (11.1%), cyclophosphamide (7.7%), fludarabine (6.2%) and other treatments (28.1%). ConClusions: The majority of patients being diagnosed with CLL did not require treatment within a time period of a year. Approximately 1/3 of patients had a second malignancy, predominantly skin cancer. Treatment was primarily composed of chemotherapy or chemoimmunotherapy.objeCtives: To estimate the annual number of patients in France with Acute Myeloid Leukemia (AML) and MyeloDysplasic Syndrom (MDS) and treated with intensive chemotherapy susceptible to induce neutropenia. Methods: French hospital databases named PMSI record medical information about all the hospitalizations performed annually in France. From 2006 to 2012, databases allow linking the stays over time of a given patient with an anonymous number. In this study, PMSI databases were used to identify patient, aged more than 15, with diagnosis of AML or MDS and who were alive during the year 2012. Then, patients who underwent hospital stays for chemotherapy during more than 5 days were identified and considered as neutropenic according to experts opinions. Results: Since 2006, 51,386 patients with at least one diagnosis of AML or MDS and aged more than 15 were identified, from which only, 16,006 had at least one hospital stay in 2012 and 3,468 were hospitalized more than 5 days for chemotherapy. Among those patients, 55.2% were male, mean age was 60.4 years, 30% died during a hospital stay and 19% (664) were bone marrow grafted during the year 2012. These patients had 1.8 stays for chemotherapy per year with average chemotherapy duration of 27 days. Two third of these patients (34%) were diagnosed in 2012 and 23% in 2011. ConClusions: Among the 16,006 patients diagnosed AML or SMD and hospitalized in France in 2012, 3, 468 (21%) received intensive chemotherapy inducing neutropenia, putting them at high risk of invasive fungal infection.

A661we used the Medicare LDS 5% sample including years 2011-2013. MG patients were identified using the ICD-9 code 358.0 and were required to have at least two diagnoses. MG patients were indexed in the year 2012 and followed for a period of one year to assess costs and healthcare utilization. Results: We identified 2,047 MG, 1,050 male and 997 female, patients in the Medicare sample giving a prevalence of 77/100,000. Male and female prevalences were 68 and 87/100,000, respectively. On average, male patient were older than females by 2.66 years (p= 0.01), had higher CCI scores (2.59 males, 2.21 for females, p= 0.01) and were less likely to be receiving Medicare disability benefits (16.67% and 25.68%, p= 0.01). Female MG patients were more frequently in the highest category for inpatients stays (12.94%, 9.14%, p= 0.03) and ER visits (36.81%, 31.81%, p= 0.01). ConClusions: Among Medicare beneficiaries MG is more prevalent than in the US population. Large differences seen in the literature between male and female patients were not seen, most likely due to the specific nature of the Medicare beneficiary population. Female MG patients had higher rates of healthcare utilization, but cost differences were negligible.

Single-arm trials have played a major role in assessing the efficacy of interferon-free antiviral regimens for hepatitis C genotype 1. To facilitate evidence synthesis, we have devised methods to integrate single-arm evidence into the network meta-analysis (NMA) framework to indirectly compare interferon-free and interferon-containing antiviral regimens. Methods: We conducted a system

A529remain at year 2013 level, and these were then combined with official population forecasts. Results: Altogether 160,952 individuals (81% of all inhabitants) had at least one healthcare contact during the follow up. Primary and secondary healthcare services had been used by 155,631 and 59,589 patients, respectively. The average annual cost per patient was 1,853€ . The average cost in primary and secondary healthcare was 808€ and 2,895€ , respectively. Variation was wide across the different ages (Primary healthcare, range: 346€ -5,645€ ; Secondary healthcare, range: 1,282€ -4,474€ ). Due to aging of the population only, according to the future projections, in the year 2025, the total primary healthcare costs are 21% and secondary healthcare costs 14% higher than in 2013. ConClusions: With respect to costs, aging of the population affects primary healthcare more than specialized healthcare. Thus, the healthcare utilization should be regarded as one entity taking into account both primary and secondary healthcare services. If the overall treatment process, from primary care to secondary care and sometimes back to primary care, is not taken in to account, this will lead to suboptimal decision making.